 | • レポートコード：MRC2208A0027 • 出版社/出版日：Transparency Market Research / 2022年6月 • レポート形態：英文、PDF、222ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査資料では、世界のがん免疫療法市場について広く調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療タイプ別（モノクローナル抗体、免疫チェックポイント阻害剤、PD-1/PD-L1、CTLA-4、その他）分析、治療領域別分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などをまとめました。なお、当書に掲載されている企業情報には、Amgen, Inc.、Bristol-Myers Squibb Company、AstraZeneca plc、GlaxoSmithKline plc、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Sanofi、Janssen Biotech, Inc.、Merck & Co., Inc.、Pfizer, Inc.、Spectrum Pharmaceuticals, Inc.などが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のがん免疫療法市場規模：治療タイプ別（モノクローナル抗体、免疫チェックポイント阻害剤、PD-1/PD-L1、CTLA-4、その他） ・世界のがん免疫療法市場規模：治療領域別 ・世界のがん免疫療法市場規模：エンドユーザー別 ・世界のがん免疫療法市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Cancer Immunotherapy Market – Scope of Report
TMR’s report on the global cancer immunotherapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global cancer immunotherapy market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer immunotherapy market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cancer immunotherapy market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cancer immunotherapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global cancer immunotherapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cancer immunotherapy market.
The report delves into the competitive landscape of the global cancer immunotherapy market. Key players operating in the global cancer immunotherapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cancer immunotherapy market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market cancer immunotherapy.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Immunotherapy Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Value Chain Analysis
5.2. Pipeline Analysis
5.3. Cancer Epidemiology
5.4. COVID-19 impact
6. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Immune Checkpoint Inhibitors
6.3.3. PD-1/PD-L1
6.3.4. CTLA-4
6.3.5. Immune System Modulators
6.3.6. Cancer Vaccines
6.3.7. Others
6.4. Market Attractiveness Analysis, by Therapy Type
7. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapeutic Area, 2017–2031
7.3.1. Lung Cancer
7.3.2. Colorectal Cancer
7.3.3. Breast Cancer
7.3.4. Prostate Cancer
7.3.5. Melanoma
7.3.6. Blood Cancer
7.3.7. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area
8. Global Cancer Immunotherapy Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers (ASCs)
8.3.3. Cancer Research Centers
8.3.4. Clinics
8.4. Market Attractiveness Analysis, by End-user
9. Global Cancer Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Immune Checkpoint Inhibitors
10.2.3. PD-1/PD-L1
10.2.4. CTLA-4
10.2.5. Immune System Modulators
10.2.6. Cancer Vaccines
10.2.7. Others
10.3. Market Value Forecast, by Therapeutic Area, 2017–2031
10.3.1. Lung Cancer
10.3.2. Colorectal Cancer
10.3.3. Breast Cancer
10.3.4. Prostate Cancer
10.3.5. Melanoma
10.3.6. Blood Cancer
10.3.7. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers (ASCs)
10.4.3. Cancer Research Centers
10.4.4. Clinics
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Therapy Type
10.6.2. By Therapeutic Area
10.6.3. By End-user
10.6.4. By Country
11. Europe Cancer Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Immune Checkpoint Inhibitors
11.2.3. PD-1/PD-L1
11.2.4. CTLA-4
11.2.5. Immune System Modulators
11.2.6. Cancer Vaccines
11.2.7. Others
11.3. Market Value Forecast, by Therapeutic Area, 2017–2031
11.3.1. Lung Cancer
11.3.2. Colorectal Cancer
11.3.3. Breast Cancer
11.3.4. Prostate Cancer
11.3.5. Melanoma
11.3.6. Blood Cancer
11.3.7. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers (ASCs)
11.4.3. Cancer Research Centers
11.4.4. Clinics
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Therapy Type
11.6.2. By Therapeutic Area
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Immune Checkpoint Inhibitors
12.2.3. PD-1/PD-L1
12.2.4. CTLA-4
12.2.5. Immune System Modulators
12.2.6. Cancer Vaccines
12.2.7. Others
12.3. Market Value Forecast, by Therapeutic Area, 2017–2031
12.3.1. Lung Cancer
12.3.2. Colorectal Cancer
12.3.3. Breast Cancer
12.3.4. Prostate Cancer
12.3.5. Melanoma
12.3.6. Blood Cancer
12.3.7. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers (ASCs)
12.4.3. Cancer Research Centers
12.4.4. Clinics
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Therapy Type
12.6.2. By Therapeutic Area
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Cancer Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Immune Checkpoint Inhibitors
13.2.3. PD-1/PD-L1
13.2.4. CTLA-4
13.2.5. Immune System Modulators
13.2.6. Cancer Vaccines
13.2.7. Others
13.3. Market Value Forecast, by Therapeutic Area, 2017–2031
13.3.1. Lung Cancer
13.3.2. Colorectal Cancer
13.3.3. Breast Cancer
13.3.4. Prostate Cancer
13.3.5. Melanoma
13.3.6. Blood Cancer
13.3.7. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers (ASCs)
13.4.3. Cancer Research Centers
13.4.4. Clinics
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Therapy Type
13.6.2. By Therapeutic Area
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Immunotherapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Immune Checkpoint Inhibitors
14.2.3. PD-1/PD-L1
14.2.4. CTLA-4
14.2.5. Immune System Modulators
14.2.6. Cancer Vaccines
14.2.7. Others
14.3. Market Value Forecast, by Therapeutic Area, 2017–2031
14.3.1. Lung Cancer
14.3.2. Colorectal Cancer
14.3.3. Breast Cancer
14.3.4. Prostate Cancer
14.3.5. Melanoma
14.3.6. Blood Cancer
14.3.7. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers (ASCs)
14.4.3. Cancer Research Centers
14.4.4. Clinics
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Therapy Type
14.6.2. By Therapeutic Area
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Analysis
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Analysis
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Bristol-Myers Squibb Company
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Analysis
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Analysis
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Spectrum Pharmaceuticals
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Analysis
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. GlaxoSmithKline plc
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Analysis
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Analysis
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. AstraZeneca plc
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Analysis
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Eli Lilly and Company.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Analysis
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Takeda Pharmaceuticals
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Analysis
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
Table 01: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031
Table 02: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031
Table 03: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031
Table 04: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2022 and 2031
Table 05: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country, 2022 and 2031
Table 06: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031
Table 07: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031
Table 08: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031
Table 09: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031
Table 10: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031
Table 11: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031
Table 12: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031
Table 13: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031
Table 14: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031
Table 15: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031
Table 16: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031
Table 17: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031
Table 18: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031
Table 19: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by therapeutic Area, 2022 and 2031
Table 20: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031
Table 21: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031
Table 22: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031
Table 23: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area 2022 and 2031
Table 24: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user 2022 and 2031